期刊文献+

溶血磷脂酸受体3在女性恶性肿瘤中的研究进展

Research Progress of Lysophosphatidic Acid Receptor 3 in Female Malignant Tumors
下载PDF
导出
摘要 溶血磷脂酸受体3(LPAR3)是G-蛋白偶联受体家族成员,可在溶血磷脂酸(LPA)的诱导下触发细胞内信号转导,从而使细胞增殖、存活、浸染,可以增强肿瘤细胞的运动,促进肿瘤细胞转移和侵袭等。女性生殖系统常见的恶性肿瘤包括卵巢癌、宫颈癌、子宫内膜癌及乳腺癌,严重威胁着女性的生命健康。LPAR3与女性恶性肿瘤的发生和发展过程有着密切的关系,因此本文对LPAR3在女性恶性肿瘤中的研究展开综述,以期对LPAR3作为癌症治疗的潜在靶点提供一些有价值的信息。 Lysophosphatidic acid receptor 3(LPAR3) is a member of the G-protein-coupled receptor family,which can trigger intracellular signal transduction under the induction of lysophosphatidic acid(LPA),thereby enabling cell proliferation,survival,and infiltration,and enhance the movement of tumor cells and promote tumor cell metastasis and invasion.The common malignant tumors of the female reproductive system are ovarian cancer,cervical cancer,endometrial cancer,and breast cancer,which seriously threaten women's lives and health.LPAR3 is closely related to the occurrence and development of female malignancies,so this paper reviews the research of LPAR3 in female malignancies,with a view to providing some valuable information on LPAR3 as a potential target for cancer treatment.
作者 谭晓丽 阮乔 于德清 陈吉霜 TAN Xiaoi;RUAN Qiao;YU Deqing;CHEN Jishuang(School of Pharmaceutical Engineering,Chongqing Chemical Industry Vocational College,Chongqing 401228,China)
出处 《生物化工》 CAS 2023年第4期180-183,共4页 Biological Chemical Engineering
关键词 溶血磷脂酸 溶血磷脂酸受体3 女性恶性肿瘤 lysophosphatidic acid lysophosphatidic acid receptor 3 malignant tumors in women
  • 相关文献

参考文献12

二级参考文献48

  • 1郭红燕,韩劲松,伍期专,杨池荪.血浆溶血磷脂酸在卵巢上皮性癌诊断中的应用初探[J].中国妇产科临床杂志,2002,3(1):36-38. 被引量:9
  • 2涂福平,陶敏,白霞,段卫明,王振欣.溶血磷脂酸受体-1在乳腺癌组织中的表达[J].临床肿瘤学杂志,2006,11(5):339-342. 被引量:3
  • 3劳明,潘忠勉,黄文成,黄玲莎,朱波,赵惠柳,李佩章,雷考宁,李晖.血浆溶血磷脂酸检测在妇科恶性肿瘤诊断中的应用研究[J].实用癌症杂志,2007,22(4):347-349. 被引量:8
  • 4Meng YR, Kang SJ, David A, et al. Lyophophatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelia ovarian cancer [ J ]. FEBS Letter,2005,579 : 1311. 被引量:1
  • 5Meng YR, Kang SJ, David A, et al. Lyophophatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells [ J ]. Cancer Immunol Immunother,2005,54 : 807. 被引量:1
  • 6Fang XJ, Yu SX, Robert C, et al. Mechanisms for Lysophosphatidic acid-induced cytokine production in ovarian cancer cells [ J ]. Biol Chem, 2004,279 (10) :9653. 被引量:1
  • 7Benjamin MS, Guiying H, Bei HM, et al. Lysopbosphalipids increase interleukin-8 expression in ovarian cancer cells [ J ]. Gynecol Oncol,2001,81:291. 被引量:1
  • 8Zakrzewska I, Poznanski J. Changes of serum il-6 and CRP after chemotherapy in patients with ovarian carcinoma [ J ]. Pol Merkuriusz Lek,2001,11 (63) :210. 被引量:1
  • 9Nowak M, Szpakowski M, Malinowski A, et al. Serum cytokincs in patients with ovarian cancer and benign ovarian cysts [ J ]. Ginekol Pol,2001,72 (12A) : 1444. 被引量:1
  • 10Fujita T, Miyamoto S, Onoyama I, et al. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer [ J]. Cancer Letters, 2003,192 ( 2 ) : 161. 被引量:1

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部